We are conducting a multicenter, randomized, controlled, prospective, open trial to evaluate both the efficacy and toxicity of nevirapine (NVP) (given twice [BID] or once daily [QD]) in virologically-suppressed patients on a PIbased HAART. NVP BID dosing is maintained for 2 months after the switch in both groups.
Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing / Sotgiu, G., Brandolini, M., Cattelan, A.M., Orani, A., Sighinolfi, L., Andreoni, M., Nardini, G., Maserati, R.. - In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. - ISSN 1758-2652. - 11:Suppl. 1(2008), p. 56. (9. International Congress on Drug Therapy in HIV Infection ) [10.1186/1758-2652-11-S1-P56].
Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing
Sotgiu, Giovanni;
2008-01-01
Abstract
We are conducting a multicenter, randomized, controlled, prospective, open trial to evaluate both the efficacy and toxicity of nevirapine (NVP) (given twice [BID] or once daily [QD]) in virologically-suppressed patients on a PIbased HAART. NVP BID dosing is maintained for 2 months after the switch in both groups.| File | Dimensione | Formato | |
|---|---|---|---|
|
Brandolini_M_Articolo_2008_Switching.pdf
accesso aperto
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
Non specificato
Dimensione
132.41 kB
Formato
Adobe PDF
|
132.41 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
